REGULATORY AFFAIRS CERTIFICATION (RAC) PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://rac.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. **What document is discussed during a meeting after a deficiency is noted in a Preapproval Inspection?**

   A. Form FDA 483

   B. Investigational New Drug Application

   C. New Drug Application

   D. Product recall notice

2. **What is meant by "pre-market" regulatory activities?**

   A. Activities after a product is launched

   B. Activities to monitor product quality post-approval

   C. Activities prior to FDA approval

   D. Activities to enhance market visibility of drugs

3. **At what timeframe after submitting an NDA will FDA provide the organization with an opportunity to meet with agency reviewing officials to inform applicants of the general progress and status of their application?**

   A. 60-day conference.

   B. 90-day conference.

   C. 120-day conference.

   D. 180-day conference.

4. **Which process allows a manufacturer to request FDA review of a new medical device?**

   A. Pre-market Approval (PMA)

   B. Investigational Device Exemption (IDE)

   C. Premarket Notification (510(k))

   D. Clinical Trial Application (CTA)

5. **A deficiency letter may be issued during the review of a Biologics License Application (BLA) if:**

   A. The BLA was not submitted electronically

   B. The sponsor failed to have a meeting with FDA

   C. Clinical testing was not performed at enough sites

   D. The submission did not include a Drug Master File

SAMPLE

6. Which statement is NOT true regarding IND Applications and IDEs for significant-risk products?

A. The investigational product must be manufactured in full compliance with CGMP

B. Clinical studies must be reviewed and approved by an IRB

C. The IND or IDE goes into effect 30 days after submission if no response is received from FDA

D. The application must include an environmental risk assessment or a categorical exclusion

7. What does a Warning Letter from the FDA indicate?

A. A notification of new product launches

B. A notification of violations that require prompt correction

C. A report on compliance audits

D. A request for additional product information

8. Which type of protocol is NOT eligible for a Special Protocol Assessment review process with the FDA?

A. A Animal carcinogenicity protocols

B. B Stability protocols

C. C Phase 3 protocols

D. D Dose ranging protocols

9. Why is tracking and handling adverse events important?

A. To increase sales of pharmaceutical products

B. To monitor product safety and identify potential issues

C. To optimize marketing techniques for drugs

D. To reduce the costs associated with drug production

10. Which action should NOT be taken after receiving a vote of "non-approvable" from an FDA Advisory Panel?

A. Continue marketing the device for its Class II classification

B. Update the current labeling to include the new indication

C. Proceed with a PMA submission to FDA

D. Request a post-panel meeting with the FDA

SAMPLE

Answers

SAMPLE

1. A
2. C
3. B
4. C
5. C
6. A
7. B
8. D
9. B
10. B

SAMPLE

Explanations

SAMPLE

1. What document is discussed during a meeting after a deficiency is noted in a Preapproval Inspection?

A. Form FDA 483

B. Investigational New Drug Application

C. New Drug Application

D. Product recall notice

The Form FDA 483 is the correct document discussed during a meeting after a deficiency is noted in a Preapproval Inspection. This form is issued by the Food and Drug Administration (FDA) to provide a summary of significant deficiencies observed during the inspection. It serves as a communication tool between the FDA and the inspected entity, highlighting any issues that must be addressed before the approval of a new drug or biologic can proceed. The significance of the Form FDA 483 lies in its role in regulatory compliance; it lists observations that may potentially violate Good Manufacturing Practice (GMP) regulations. After the issuance of a Form FDA 483, the company involved is expected to respond with corrective actions and a plan to rectify the noted deficiencies. This discussion is critical for ensuring that any compliance issues are resolved and does not delay the drug approval process. Investigational New Drug Applications and New Drug Applications are key documents in the drug approval process but are not specifically focused on deficiencies noted during inspections. A product recall notice pertains to actions taken after a product has been approved and is on the market, addressing safety issues rather than deficiencies found during inspections. Thus, these documents do not fit the context of a meeting initiated due to inspection findings.

2. What is meant by "pre-market" regulatory activities?

A. Activities after a product is launched

B. Activities to monitor product quality post-approval

C. Activities prior to FDA approval

D. Activities to enhance market visibility of drugs

"Pre-market" regulatory activities refer to the processes and actions taken before a product, such as a drug or medical device, is approved for sale by regulatory authorities like the FDA. This encompasses a variety of efforts, including conducting clinical trials to assess safety and efficacy, compiling and submitting a comprehensive application for approval (such as a New Drug Application or Premarket Approval application), and engaging in discussions with regulatory agencies to ensure all necessary data and documentation are presented for evaluation. These activities are crucial for establishing the safety profile, effectiveness, and overall quality of a product prior to its introduction to the market. Successful completion of these activities leads to gaining regulatory approval, allowing the product to be marketed and made available to patients and healthcare providers. The focus on pre-market activities underscores the importance of thorough assessment in the regulatory process to protect public health and ensure that only safe and effective products reach consumers.

SAMPLE

3. At what timeframe after submitting an NDA will FDA provide the organization with an opportunity to meet with agency reviewing officials to inform applicants of the general progress and status of their application?

A. 60-day conference.

B. 90-day conference.

C. 120-day conference.

D. 180-day conference.

The timeframe for the FDA to provide an opportunity for applicants to meet with agency reviewing officials after submitting a New Drug Application (NDA) is set at 90 days. This 90-day conference serves as a crucial checkpoint in the review process where the FDA communicates the general progress and status of the NDA. This meeting allows the applicant to gain insights into any issues or concerns that may have arisen during the review and to discuss the path forward. During this conference, the applicant can address specific aspects of the application and understand better the FDA's perspective and any additional information or data that may be required. This meeting is a part of the FDA's commitment to maintaining open communication with applicants during the review process, fostering collaboration, and ensuring that the application meets the regulatory requirements efficiently as it progresses through the review timeline.

4. Which process allows a manufacturer to request FDA review of a new medical device?

A. Pre-market Approval (PMA)

B. Investigational Device Exemption (IDE)

C. Premarket Notification (510(k))

D. Clinical Trial Application (CTA)

The process that allows a manufacturer to request FDA review of a new medical device is the Premarket Notification, commonly known as 510(k). This process is designed for devices that are substantially equivalent to one or more legally marketed devices. When a manufacturer submits a 510(k), they provide evidence to demonstrate that their device is safe and effective based on the comparison to an already approved device. One of the advantages of the 510(k) process is that it often requires less rigorous testing than other pathways, such as Pre-market Approval (PMA), which mandates a more comprehensive review due to the potential risks associated with the device. The 510(k) pathway is commonly used for devices that are considered lower risk, allowing for a more streamlined route to market. In addition to 510(k), there are other regulatory pathways like the Investigational Device Exemption (IDE) and Clinical Trial Application (CTA), but these are typically used for devices in the investigational stage or those undergoing clinical trials, rather than for the initial review for market entry. Therefore, 510(k) is the specific mechanism utilized for initiating the FDA review for many new medical devices seeking to demonstrate substantial equivalence.

SAMPLE

5. A deficiency letter may be issued during the review of a Biologics License Application (BLA) if:

A. The BLA was not submitted electronically

B. The sponsor failed to have a meeting with FDA

C. Clinical testing was not performed at enough sites

D. The submission did not include a Drug Master File

A deficiency letter can be issued during the review of a Biologics License Application (BLA) when critical aspects of the application do not meet regulatory requirements or standards, which can lead to concerns regarding the safety, efficacy, or quality of the biologic product. The rationale behind the correct choice centers on the necessity of having comprehensive and robust clinical testing for approval. Clinical testing plays a pivotal role in establishing a product's safety and efficacy. When clinical studies are not sufficiently comprehensive—such as being limited to an inadequate number of sites—it raises concerns about the validity of the results, potential biases, and the overall generalizability of the data. A thorough clinical assessment is crucial; therefore, inadequate site availability can substantially impact the review process, prompting the agency to issue a deficiency letter until these concerns are adequately addressed. In contrast, the other options do not directly pertain to the core requirements for the review of the BLA concerning the product's safety and efficacy. The electronic submission requirement is a procedural issue rather than a definitive lack of clinical data. Meeting with the FDA, while useful, is not mandatory for every BLA and does not inherently lead to a deficiency if skipped. Lastly, while a Drug Master File may contain important information, its absence

6. Which statement is NOT true regarding IND Applications and IDEs for significant-risk products?

A. The investigational product must be manufactured in full compliance with CGMP

B. Clinical studies must be reviewed and approved by an IRB

C. The IND or IDE goes into effect 30 days after submission if no response is received from FDA

D. The application must include an environmental risk assessment or a categorical exclusion

The statement that is not true regarding IND Applications and IDEs for significant-risk products is the assertion that the investigational product must be manufactured in full compliance with Current Good Manufacturing Practices (CGMP). While it is indeed essential that investigational products are produced using appropriate quality standards, the FDA does allow for certain flexibility with respect to CGMP compliance in the context of investigational products. Specifically, the FDA recognizes that these products are in the exploratory phase, and thus, the strict application of CGMP requirements might not be as stringent as it would be for commercially marketed products. In contrast, clinical studies associated with IND and IDE submissions must be reviewed and approved by an Institutional Review Board (IRB), ensuring that the rights and welfare of the human subjects are protected. Furthermore, if the FDA does not respond within 30 days of submission, the IND or IDE is considered to be effective, allowing the sponsor to proceed with the clinical investigation. Lastly, the requirement for an environmental risk assessment or a categorical exclusion is part of the regulatory framework designed to evaluate the environmental impact of the investigational drugs, underscoring the regulatory body's commitment to environmental protection.

SAMPLE

7. What does a Warning Letter from the FDA indicate?

A. A notification of new product launches

B. A notification of violations that require prompt correction

C. A report on compliance audits

D. A request for additional product information

A Warning Letter from the FDA is a serious notification that highlights violations of regulatory standards that the FDA has identified during inspections or through other monitoring processes. The primary purpose of issuing a Warning Letter is to inform the recipient of these violations and to demand prompt corrective action to address them. The FDA expects that the violations will be remedied in a timely manner to ensure continued compliance with regulations that protect public health. This communication is not merely informational; it serves as an official indication that the agency views the identified issues as significant and requiring immediate remedy. Unlike product launch notifications or requests for additional product information, which do not imply regulatory non-compliance, and compliance audit reports, which are typically internal documents, a Warning Letter distinctly aims to rectify issues that could potentially affect the safety and effectiveness of products in the market.

8. Which type of protocol is NOT eligible for a Special Protocol Assessment review process with the FDA?

A. A Animal carcinogenicity protocols

B. B Stability protocols

C. C Phase 3 protocols

D. D Dose ranging protocols

The Special Protocol Assessment (SPA) is a process offered by the FDA to provide sponsors with the opportunity to receive written agreement on the design and planned analysis of certain types of clinical trial protocols intended to support regulatory submissions. The SPA is useful in ensuring that the study design addresses the FDA's expectations regarding the trials that will have a direct effect on marketing approval. Protocols that are eligible for SPA typically include pivotal trials, especially those conducted in late-phase development, such as Phase 3 protocols, which are specifically designed to confirm the efficacy and safety of a drug in a larger population before it gains market approval. In contrast, dose-ranging protocols are generally used to establish the optimal dose for subsequent studies, often prior to Phase 3 trials, which means they are not yet pivotal to demonstrating safety or efficacy for regulatory approval. This distinction is key because the SPA is reserved for studies where there is a clear and substantial regulatory path towards determining whether a drug is approvable or not, which does not apply to exploratory studies like dose-ranging protocols. Other types of protocols, such as animal carcinogenicity protocols and stability protocols, also play important roles in the development process but do not align with the eligibility criteria established for the SPA designation, which focuses on specific trials

SAMPLE

9. Why is tracking and handling adverse events important?

A. To increase sales of pharmaceutical products

B. To monitor product safety and identify potential issues

C. To optimize marketing techniques for drugs

D. To reduce the costs associated with drug production

Tracking and handling adverse events is crucial because it allows regulatory authorities, healthcare professionals, and manufacturers to monitor the safety profile of pharmaceutical products. By documenting and analyzing adverse events, organizations can identify patterns or signals that may indicate potential safety concerns. This process enables timely interventions to mitigate risks, enhances the understanding of the product's safety in real-world settings, and aids in informed decision-making regarding the continued use of the product, labeling changes, or even product withdrawal. Additionally, thorough tracking of adverse events contributes to regulatory compliance, as agencies like the FDA or EMA require manufacturers to report any adverse events associated with their products. This ensures that patients and healthcare providers are well-informed about the risks involved in using a particular treatment, ultimately protecting public health. In contrast, options that focus on increasing sales, optimizing marketing techniques, or reducing production costs do not align with the primary purpose of adverse event tracking, which is centered around patient safety and risk management rather than commercial interests.

10. Which action should NOT be taken after receiving a vote of "non-approvable" from an FDA Advisory Panel?

A. Continue marketing the device for its Class II classification

B. Update the current labeling to include the new indication

C. Proceed with a PMA submission to FDA

D. Request a post-panel meeting with the FDA

The action that should not be taken after receiving a vote of "non-approvable" from an FDA Advisory Panel is the update of current labeling to include the new indication. When an Advisory Panel votes non-approvable, it indicates that the panel has identified significant issues or deficiencies with the product, which precludes the approval of the new indication. Therefore, any attempt to update the labeling would be inappropriate, as it would suggest that the device is approved for that indication when it is not. In this context, continuing marketing the device for its existing Class II classification, proceeding with a PMA submission, and requesting a post-panel meeting with the FDA are actions that can be taken. Continuing to market a device already classified as Class II is permissible unless the marketing is directly tied to the indication that was non-approvable. A PMA submission could still be explored if there is sufficient data supporting the product, independent of the non-approvable indication. Lastly, requesting a post-panel meeting can provide valuable feedback from the FDA on how to address the panel's concerns and potentially find a pathway to approval in the future.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://rac.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE